Background: Cervical cancer remains a leading cause of cancer-related morbidity and mortality in Africa, where progress toward WHO’s 90–70–90 elimination targets has been limited by structural health inequalities and gaps in prevention services.

Methods: We conducted a comprehensive analysis of cervical cancer burden across the African Union from 1990 to 2023, using data from the Global Burden of Disease Study 2023. Four key indicators—incidence, prevalence, mortality, and disability-adjusted life years (DALYs)—were extracted and stratified by region and age group. Estimated Annual Percentage Change (EAPC) was calculated to assess long-term trends, while age-specific and regional disparities were evaluated. Future burden was projected to 2038 using the Autoregressive Integrated Moving Average (ARIMA) model.

Results: While global cervical cancer rates have declined modestly since 1990, Africa has experienced rising trends across all indicators. From 1990 to 2023, the age-standardised incidence rate in the African Union rose from 17.41 to 23.53 per 100,000 population (EAPC = 0.67, 95% CI: 0.48–0.87), and DALYs increased from 368.58 to 430.7 per 100,000 (EAPC = 0.24, 95% CI: 0.07–0.41). Central, Southern, and Eastern Africa showed the highest burden, with Southern Africa recording the most rapid increase in incidence (EAPC = 1.54). Age-specific analysis revealed a concentrated burden among women aged 40–54, with absolute case numbers nearly doubling in this group since 1990. Projections suggest a substantial increase in incidence, prevalence, deaths and DALYs by 2038, and the gap between Africa and the global average is expected to widen further, with incidence rates remaining significantly above the WHO elimination threshold of <4/100,000.

Conclusion: Africa’s cervical cancer burden is increasing and diverging from global progress. Structural health system limitations, insufficient HPV vaccination coverage, and low screening uptake are key contributors. Urgent, region-specific interventions—integrating prevention, screening, and treatment—are essential to reverse current trends and achieve WHO elimination goals.

GAnnoViz a cloud-integrated framework for chromosome-level feature annotation and visualization in biomedical multi-omics. Encompassing 30+ analytical and visualization modules across five key areas: acquisition of species genomic annotations, extraction of genomic features, drawing of gene structures, sliding window annotation, and chromosome-scale visualization of multi-omics. It supports genomic annotation retrieval for 349 species from Ensembl, newly assembled genome with GFF3 or GTF format, and an interactive interface deployed on the HiPlot cloud platform.

In two independent cohorts of 10,938 American and 352,980 UK adults aged ≥45 years, the a body shape index (ABSI) showed consistent and comparative stronger associations with all-cause, cardiovascular, and cancer mortalities among 8 adiposity surrogates. Underlying explanations may involve multiple diseases across diverse systems, notably atherosclerosis, non-alcoholic fatty liver disease, type 2 diabetes, and hypercholesterolemia. And ABSI plays a driving role not only in the transitions from disease-free state to these 4 diseases onset, but also from diseases to death. These findings provide more evidence facilitating development and implementation of clinical guidelines for obesity assessment.

Sharing good news at work isn't always positive for everyone. Discover how power dynamics shape employees’ reactions to a supervisor’s success.

his study provides the first clinical evaluation of the combined use of microneedling and PRX PLUS for multidimensional skin quality improvement. By integrating objective imaging-based assessments (VISIA® and Visioscope) with patient-reported outcomes, the study demonstrates potential benefits of this minimally invasive approach in improving skin texture, pigmentation, redness, pore visibility, and overall facial appearance. These findings provide preliminary clinical evidence supporting regenerative, low-downtime strategies for skin rejuvenation and highlight the need for further controlled studies to validate the efficacy and underlying mechanisms of this combined protocol.

With the advancement of long-term crewed deep-space exploration missions, the effects of the microgravity environment on astronauts' brain function have become an important topic in aerospace medicine. The disappearance of the hydrostatic pressure gradient during spaceflight induces cephalad fluid shifts, which can alter cerebral blood flow (CBF) and are closely associated with visual impairment, spatial disorientation, and cognitive decline. However, existing studies have predominantly focused on the steady-state phase during the middle and late stages of microgravity exposure, with insufficient understanding of the characteristics of CBF fluctuations during the early phase of postural transitions. Moreover, as an indicator of terminal perfusion in the cerebral microcirculation, the coupling relationship between CBF and the upstream hemodynamics of the internal carotid and vertebral arteries has not been systematically investigated. In addition, magnetic resonance imaging (MRI) cannot be applied in real time during spaceflight due to its bulky equipment, whereas ultrasound offers the advantages of portability, real-time capability, and radiation-free operation. Therefore, elucidating the association between early macrovascular hemodynamic changes under simulated microgravity and regional CBF alterations, and evaluating the feasibility of using ultrasound parameters as portable predictors of CBF, holds significant scientific importance and application value.